Ann: Prescient unveiling CellPryme-A at CAR-TCR summit in Boston, page-8

It states "Novel Universal Immune Receptor". I'd been doing some back-research yesterday on our patent submissions and noticed that our provisional status had been updated with the following info, which suggests that all our CellPryme-A documentation has now been filed under the standard patent application!



More importantly, the following suggests that CP-A is very much specific to OmniCAR and that UPenn's patent and ours will overlap:-




So, basically whiilst CellPryme-A is specific to the activation stage of the manufacturing process, it has specific correlation and synergies to OmniCAR.